HIF-1alpha in lung carcinoma: Histopathological evidence of hypoxia targets in patient biopsies

Maria Ioannou, George Simos, George K Koukoulis

Abstract


Background: Hypoxia inducible factor 1alpha (HIF-1alpha) plays a major role in the response of tumors to hypoxia, and contributes to tumor aggressiveness, invasiveness and resistance to radiotherapy and chemotherapy. Targeting HIF-1alpha is an attractive strategy, with the potential for disrupting multiple pathways crucial for tumor growth. Thus, the evaluation of HIF-1alpha in patient biopsies could be useful in personalized cancer treatment.

Methodology: The current literature on HIF-1alpha immunohistochemical expression is reviewed along with the relation to clinical outcome and prognosis. In addition, the significant correlation of HIF-1alpha to vascular endothelial growth factor (VEGF) expression is reported, as well as the possible role of HIF-1alpha in predicting the therapeutic response to anti-EGFR therapies.

Conclusion: Herein, an overview of the HIF-1alpha expression in lung carcinoma is presented. Since there is no consensus regarding the assessment of HIF-1alpha in tissue specimens, heterogeneous results have been reported especially regarding prognosis. In this context, methods to optimize the evaluation of HIF-1alpha in biopsies are needed in order to clarify the role of HIF-1alpha as a prognostic or predictive biomarker in lung carcinoma.

 


Full Text: PDF DOI: 10.5430/jst.v3n2p35

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

Journal of Solid Tumors

ISSN 1925-4067(Print)   ISSN 1925-4075(Online)

Copyright © Sciedu Press


To make sure that you can receive messages from us, please add the 'Sciedu.ca' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.